Logo

Tm Biosciences Closes $CA12M Private Placement

Dec 22, 2003

NEW YORK, Dec. 22 (GenomeWeb News) - Tm Biosciences of Toronto said today it had closed a $CA12 million ($9 million) private placement

 

In this placement, the publicly traded company sold 37.5 million shares at $CA.32 per unit, which includes a common share in the capital of the company and a purchase warrant for a half of a common share that can be exercised at the price of $CA.40 per share through June 2005. The $CA12 million figure represented the gross proceeds.

 

The company said the financing would be used for further development and commercialization of the company's genetic tests, which are based on its Tm 100 platform.

 

The company recently received a $CA 7.3 million investment from Technology Partnerships Canada, a Canadian government funding agency.

 

"The proceeds of this financing, together with the recently announced $7.3 million investment from Technology Partnerships Canada (TPC), provide Tm with the financial security to move into profitability," Greg Hines, President and CEO of Tm Bioscience, said in a statement.

Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.